Between Innsbruck and Munich Seefeld offers a beautiful landscape and renowned conference hotels, so the first annual partner meeting took place from March 9-10, 2016 in that inspiring surrounding area chaired by the coordinator Univ.-Prof. Dr Zlatko Trajanoski from the Medical University of Innsbruck. Representatives of all eleven partner institutes and companies met to exchange scientific results, control achievements and define next steps. Two members of the International scientific advisory board (ISAB), the ethical advisor as well as the EU project officer participated and further strengthened the progress of the project with their helpful recommendations.
Epitope-based vaccines has emerged as a promising approach to treat not only infectious diseases but also to promote the battle against cancer by a patient’s own immune system. Actually, the prediction and assembly of viable epitopes and spacers in a string-of-beads like polypeptide remain one of the challenges. The design of the spacers between the epitopes and order of the epitopes thereby seem to affect crucially the probability that the selected peptides will be fully recovered and subsequently presented by patient´s HLA molecules and that risk is reduced, that adverse neoepitopes are generated within this process.
Benjamin Schubert and Oliver Kohlbacher from the University of Tübingen proposed in their work, which recently was published in Genome Medicine, a mathematical model to design spacer sequences of optimal design. First results are promising, as they showed indeed higher recovery rates and lower neoepitope generation using the proposed framework.
Together with partners, the researchers of Tübingen are going to validate the model in experimental tests within the project APERIM. Results will show if this approach helps to improve and accelerate epitope vaccine development.
Schubert B, Kohlbacher O: Designing string-of-beads vaccines with optimal spacers, Genome Medicine 2016, 8:9 full text
Benjamin Schubert; Mathias Walzer; Hans-Philipp Brachvogel; Andras Szolek; Christopher Mohr; Oliver Kohlbacher: FRED 2 – An Immunoinformatics Framework for Python. Bioinformatics 2016; doi: 10.1093/bioinformatics/btw113 full text
Eberhard Karls University Tübingen
Applied Bioinformatics Group
Sand 14, D-72076 Tübingen
schubert (at) informatik.uni-tuebingen.de
Partner institutions of the APERIM project participated in the project kick off meeting on May 11th 2015 in Mainz. The meeting has been an excellent occasion to get to know all consortium members and to exchange in detail about the work packages and the next steps.
The Medical University of Innsbruck is coordinating the EU research project on personalised cancer immunotherapy
- The “APERIM” project will start on 1 May: Precision medicine for cancer treatment
- Cancer immunotherapy: Pioneering and targeted tumour treatment
- Only EU project on personalised medicine coordinated in Austria
In future, cancer immunotherapy is to improve treatment of tumours. For this purpose, bioinformatics specialists at the Medical University of Innsbruck are developing a new treatment platform together with immunotherapy experts. The “APERIM” EU project is the only research project coordinated in Austria from the Horizon2020 Calls in the area of personalising health and care (H2020-PHC-2014).
Innsbruck 14/04/2015: On 1 May, the Medical University of Innsbruck will start an innovative research project to implement modern, personalised cancer immunotherapy: Univ.-Prof. Dipl.-Ing. Dr. Zlatko Trajanoski, Director of the Innsbruck Division of Bioinformatics, is coordinating the APERIM “Advanced bioinformatics platform for PERsonalised cancer IMmunotherapy” project. Eight academic partners and three companies are working on practical implementation of immunotherapy specifically for unique tumour mutations of individual patients. “We are creating the conditions needed to better treat cancer with state-of-the-art precision medicine in future,” explains Trajanoski, the project coordinator. “Many research papers have shown that cancer immunotherapy is suitable for successfully treating cancer.”
The researchers will receive three million euros in funding via the Horizon 2020 EU Grant Programme. Univ.-Prof Trajanoski from Innsbruck Biocenter is the only Austrian project coordinator in the “Personalising health and care” funding pool.
Immune system against cancer: Analysis of “next generation sequencing” data
The immune system protects the human body not only against foreign pathogens, but also against tumour cells. Cancer cells can escape the control of the immune system in various ways. However this reduced defensive reaction can be stimulated therapeutically, as numerous research papers have shown. The new findings and ways of obtaining more and more information from samples, known as “next generation sequencing” methods, require the development of new platforms to utilise the data to treat patients. Treatment platforms process the individual data of cancer patients to allow it to be used for therapy recommendations, for example. Bioinformatics methods permit the evaluation and processing of the specific information on the molecular fundamentals of individual tumours, which in turn forms the basis for personalised cancer immunotherapy.
“APERIM” – Four steps to personalised cancer immunotherapy
The “APERIM” project has four goals: A new database will store all molecular information on a tumour, a new analysis tool will permit quantification of tumour-infiltrated T cells, a software application will provide the information required to produce personalised, therapeutic vaccinations and a new method will be used to develop a special T cell gene therapy.
Univ.-Prof. Trajanoski and his colleagues plan to develop a database in which all information on a tumour – i.e. findings from the histopathological image analysis as well as genetic and clinical data – can be entered. That allows all molecular properties and specific mutations of a tumour to be stored and retreived. “This comprehensive information will then provide an important foundation for diagnosis and therapy,” explains Univ.-Prof Trajanoski, the project coordinator.
The second step will be the development of a tool for quantifying tumour-infiltrated T cells. “It is essential to determine the density and the subpopulations of the tumour-infiltrated T cells precisely to be able to identify high-risk patients. The more specific immune cells are infiltrating, the higher the chances of survival of cancer patients,” explains the expert.
The third project section will develop software to identify antigens for the development of individualised cancer vaccination based on the comprehensive detailed information. Every tumour has different properties, which makes it impossible to develop a single vaccination for a type of cancer. “Therapeutic vaccinations of this kind for treating cancer must be personalised and the software must facilitate the analysis required for this,” adds Trajanoski.
The fourth and last project target is a vision for the future in particular, as there have only been a few experimental studies to date. “We want to develop a new method which makes it possible to predict the antigen specificity and tumour activity of the T cells. Based on this information, individual T cell gene